Research map: Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents

Back to the article

Papers in this map

  1. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 · Deborah Steensels · 2021 · 391 citations · Cited by this paper
  2. The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions · Chalothorn Wannaphut · 2026 · Related
  3. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273 · Shyh Poh Teo · 2021 · 195 citations · Cited by this paper
  4. Pneumococcal vaccination awareness and uptake among high-risk patients attending internal medicine outpatient clinics: A cross-sectional study · 2026 · Related
  5. The effect of aging of the immune system on vaccination responses · Janet M. Lord · 2013 · 158 citations · Cited by this paper
  6. Route of BCG administration determines success · 2026 · Related
  7. Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults · Mark A. Brockman · 2021 · 108 citations · Cited by this paper
  8. Safety monitoring of bivalent, quadrivalent, and 9-valent human papillomavirus vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study · 2026 · Related
  9. Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies · Yingying Hou · 2024 · 108 citations · Cited by this paper
  10. Immunological insights into why pertussis continues to be endemic · 2026 · Related
  11. Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents · David H. Canaday · 2021 · 104 citations · Cited by this paper
  12. Vaccination coverage and influencing factors of four non‑National Immunization Program vaccines: A cross‑sectional survey among children aged 1‒6 years in Beijing, China · 2026 · Related
  13. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021 · Kristina L. Bajema · 2021 · 90 citations · Cited by this paper
  14. Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan’s pediatric National Immunization Program and impacts of a delayed implementation · 2026 · Related
  15. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study · Katia J. Bruxvoort · 2021 · 88 citations · Cited by this paper
  16. Budget impact analysis of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccination for preventing respiratory syncytial virus in Egyptian infants · 2026 · Related
  17. Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system · George N. Ioannou · 2022 · 57 citations · Cited by this paper
  18. Health-related quality of life and adverse events during 14 days after receiving a live-attenuated influenza vaccine in Japanese children 4–15 years of age · 2026 · Related
  19. COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents · David H. Canaday · 2022 · 51 citations · Cited by this paper
  20. Spatial accessibility analysis of vaccination units in Gansu Province, China (2025) · 2026 · Related
  21. Age-related changes in the immune system and challenges for the development of age-specific vaccines · Mark T. Doherty · 2025 · 48 citations · Cited by this paper
  22. Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose · Francis M. Mwimanzi · 2022 · 47 citations · Cited by this paper
  23. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis · Kevin Yau · 2022 · 43 citations · Cited by this paper
  24. Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP · William J. Hulme · 2023 · 43 citations · Cited by this paper
  25. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults · Daniel A. Harris · 2023 · 33 citations · Cited by this paper
  26. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents? · Oladayo Ayobami Oyebanji · 2021 · 25 citations · Cited by this paper
  27. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers · Wendy M. Brunner · 2022 · 18 citations · Cited by this paper
  28. Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE · Xuan Wang · 2025 · 15 citations · Cited by this paper
  29. Systematic review and meta-analysis of COVID-19 mRNA vaccine effectiveness against hospitalizations in adults · Bill Wong · 2024 · 14 citations · Cited by this paper
  30. Humoral and Cellular Response after mRNA Vaccination in Nursing Homes: Influence of Age and of History of COVID-19 · Jesús San Román · 2022 · 12 citations · Cited by this paper
  31. Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults · Geir Bredholt · 2024 · 11 citations · Cited by this paper
  32. Humoral immunity induced by mRNA COVID-19 vaccines in Nursing Home Residents previously infected with SARS-CoV-2 · Giorgio Fedele · 2022 · 10 citations · Cited by this paper
  33. Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination · Stefan Gravenstein · 2023 · 8 citations · Cited by this paper
  34. Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents · Yasin Abul · 2024 · 8 citations · Cited by this paper
  35. Humoral and Cellular Immune Responses Against SARS-CoV-2 Following COVID-19 Vaccination in Older Adults: A Systematic Review · R. A. Cruz · 2025 · 5 citations · Cited by this paper
  36. COVID-19 mRNA booster vaccination induces robust antibody responses but few adverse events among SARS-CoV-2 naïve nursing home residents · Masae Itamochi · 2024 · 3 citations · Cited by this paper
  37. Immunologic Evaluation of First and Second Doses of SARS‐CoV‐2 XBB.1.5 and the KP.2 Monovalent Booster Vaccines in Nursing Home Residents · Olajide J Olagunju · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)